知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

62 条记录 (耗时 0.037 秒)

    Formulations containing thymoquinone for urinary health
    51.
    发明授权
    Formulations containing thymoquinone for urinary health 有权
    含有胸腺醌的制剂用于尿液健康

    公开(公告)号：US08029831B2

    公开(公告)日：2011-10-04

    申请号：US12220811

    申请日：2008-07-29

    申请人： Linda M. Pacioretty ,  John G. Babish

    发明人： Linda M. Pacioretty ,  John G. Babish

    IPC分类号： A61K36/04 ,  A61K36/00

    CPC分类号： A61K31/195

    摘要： A novel dietary supplement or therapeutic composition is provided that serves to treat lower urinary tract disorders or to support normal urinary tract function in animals. The supplement comprises a thymoquinone formulation and at least one member of the group consisting of cranberry fruit, cranberry extract, cranberry juice and a pharmaceutical grade methionine.

    摘要翻译： 提供了一种新颖的膳食补充剂或治疗组合物，其用于治疗下尿路疾病或支持动物中的正常尿道功能。 补充剂包含胸腺醌配方和由蔓越莓果实，蔓越莓提取物，蔓越莓汁和药用级蛋氨酸组成的组中的至少一个成员。

    Formulations containing thymoquinone for urinary health
    54.
    发明申请
    Formulations containing thymoquinone for urinary health 有权
    含有胸腺醌的制剂用于尿液健康

    公开(公告)号：US20100028468A1

    公开(公告)日：2010-02-04

    申请号：US12220811

    申请日：2008-07-29

    申请人： Linda M. Pacioretty ,  John G. Babish

    发明人： Linda M. Pacioretty ,  John G. Babish

    IPC分类号： A61K36/45 ,  A61K31/195 ,  A61P13/00

    CPC分类号： A61K31/195

    摘要： A novel dietary supplement or therapeutic composition is provided that serves to treat lower urinary tract disorders or to support normal urinary tract function in animals. The supplement comprises a thymoquinone formulation and at least one member of the group consisting of cranberry fruit, cranberry extract, cranberry juice and a pharmaceutical grade methionine.

    摘要翻译： 提供了一种新颖的膳食补充剂或治疗组合物，其用于治疗下尿路疾病或支持动物中的正常尿道功能。 补充剂包含胸腺醌配方和由蔓越莓果实，蔓越莓提取物，蔓越莓汁和药用级蛋氨酸组成的组中的至少一个成员。

    In vitro screening assay for identification of compounds that inhibit cytopathicity of viral infection
    58.
    发明授权
    In vitro screening assay for identification of compounds that inhibit cytopathicity of viral infection 失效
    用于鉴定抑制病毒感染的细胞病变的化合物的体外筛选测定

    公开(公告)号：US6140063A

    公开(公告)日：2000-10-31

    申请号：US294442

    申请日：1998-08-13

    申请人： Geoffrey D. Wheelock ,  Joseph Rininger ,  John G. Babish ,  Padmasree Chigurupati

    发明人： Geoffrey D. Wheelock ,  Joseph Rininger ,  John G. Babish ,  Padmasree Chigurupati

    IPC分类号： A61K31/343 ,  A61K31/352 ,  A61K31/357 ,  G01N33/566 ,  G01N33/569 ,  G01N33/53

    CPC分类号： G01N33/566 ,  A61K31/343 ,  A61K31/352 ,  A61K31/357 ,  G01N33/56988 ,  G01N2500/04 ,  Y10S435/975

    摘要： The present invention includes the method of treating a viral infection, specifically one occurring as a result of infection by a human immunodeficiency virus (HIV-1). The method of treatment depends upon the ligand binding of the Ah receptor. Transformation and translocation of the receptor and DNA binding are not required. The study of compounds that interact with the Ah receptor, either as agonists, or antagonists, has resulted in the identification of compounds with useful therapeutic properties through perturbation of viral pathogenic signal transduction pathways. Antagonists of the Ah receptor are more likely candidates for treatment because the toxicity of such compounds is low. Identification of molecules affecting cellular targets, such as the Ah receptor, that inhibit viral pathologic signaling would be of great therapeutic potential as the activity of these molecules is not directed against the virus itself, therefore genetic viral mutation to escape such therapy would be far less likely to occur. The use of secondary compounds for use in combinational, synergistic, therapy is also enclosed. These second compounds are also known to have some effect on the treatment of cellular pathologic changes, together with those compounds found to be effective upon the regulation of the Ah receptor the compounds can more beneficially control virally induced cellular cytopathic changes.

    摘要翻译： 本发明包括治疗病毒感染的方法，特别是由人免疫缺陷病毒（HIV-1）感染的结果。 治疗方法取决于Ah受体的配体结合。 受体的转化和易位和DNA结合是不必要的。 与Ah受体（作为激动剂或拮抗剂）相互作用的化合物的研究已经导致通过扰动病毒致病信号转导途径鉴定具有有用治疗性质的化合物。 Ah受体的拮抗剂更可能是治疗的候选者，因为这些化合物的毒性低。 影响细胞靶标的分子的鉴定，如Ah受体，其抑制病毒病理信号传导将具有很大的治疗潜力，因为这些分子的活性不针对病毒本身，因此逃避这种治疗的遗传病毒突变将远远少于 可能发生 也包括使用二次化合物用于组合，协同治疗。 还已知这些第二化合物对细胞病理学变化的治疗具有一些作用，以及发现在调节Ah受体时有效的化合物可以更有利地控制病毒诱导的细胞病变变化。

    Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
    59.
    发明授权
    Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection 失效
    AH受体和AH受体配体的使用可以治疗或预防病毒感染的细胞病变

    公开(公告)号：US5833994A

    公开(公告)日：1998-11-10

    申请号：US780742

    申请日：1997-01-08

    申请人： Geoffrey D. Wheelock ,  Joseph Rininger ,  John G. Babish ,  Padmasree Chigurupati

    发明人： Geoffrey D. Wheelock ,  Joseph Rininger ,  John G. Babish ,  Padmasree Chigurupati

    IPC分类号： A61K31/343 ,  A61K31/352 ,  A61K31/357 ,  G01N33/566 ,  G01N33/569 ,  A01N65/00

    CPC分类号： G01N33/566 ,  A61K31/343 ,  A61K31/352 ,  A61K31/357 ,  G01N33/56988 ,  G01N2500/04 ,  Y10S435/975

    摘要： The present invention includes the method of treating a viral infection, specifically one occurring as a result of infection by a human immunodeficiency virus (HIV-1). The method of treatment depends upon the ligand binding of the Ah receptor. Transformation and translocation of the receptor and DNA binding are not required. The study of compounds that interact with the Ah receptor, either as agonists, or antagonists, has resulted in the identification of compounds with useful therapeutic properties through perturbation of viral pathogenic signal transduction pathways. Antagonists of the Ah receptor are more likely candidates for treatment because the toxicity of such compounds is low. Identification of molecules affecting cellular targets, such as the Ah receptor, that inhibit viral pathologic signaling would be of great therapeutic potential as the activity of these molecules is not directed against the virus itself, therefore genetic viral mutation to escape such therapy would be far less likely to occur. The use of secondary compounds for use in combinational, synergistic, therapy is also enclosed. These second compounds are also known to have some effect on the treatment of cellular pathologic changes, together with those compounds found to be effective upon the regulation of the Ah receptor the compounds can more beneficially control virally induced cellular cytopathic changes.

    摘要翻译： 本发明包括治疗病毒感染的方法，特别是由人免疫缺陷病毒（HIV-1）感染的结果。 治疗方法取决于Ah受体的配体结合。 受体的转化和易位和DNA结合是不必要的。 与Ah受体（作为激动剂或拮抗剂）相互作用的化合物的研究已经导致通过扰动病毒致病信号转导途径鉴定具有有用治疗性质的化合物。 Ah受体的拮抗剂更可能是治疗的候选者，因为这些化合物的毒性低。 影响细胞靶标的分子的鉴定，如Ah受体，其抑制病毒病理信号传导将具有很大的治疗潜力，因为这些分子的活性不针对病毒本身，因此逃避这种治疗的遗传病毒突变将远远少于 可能发生 也包括使用二次化合物用于组合，协同治疗。 还已知这些第二化合物对细胞病理学变化的治疗具有一些作用，以及发现在调节Ah受体时有效的化合物可以更有利地控制病毒诱导的细胞病变变化。

    Automated, multicompartmental cell culture system
    60.
    发明授权
    Automated, multicompartmental cell culture system 失效
    自动多室细胞培养系统

    公开(公告)号：US5612188A

    公开(公告)日：1997-03-18

    申请号：US194792

    申请日：1994-02-10

    申请人： Michael L. Shuler ,  John G. Babish ,  Lisa M. Sweeney ,  Brian E. Johnson

    发明人： Michael L. Shuler ,  John G. Babish ,  Lisa M. Sweeney ,  Brian E. Johnson

    IPC分类号： C12M1/34 ,  C12M1/36 ,  C12M3/00 ,  G06F19/00 ,  C12Q1/00

    CPC分类号： C12M41/34 ,  C12M21/08 ,  C12M23/58 ,  C12M29/14 ,  C12M35/08 ,  C12M37/00 ,  C12M41/48 ,  G01N33/5082 ,  G06F19/366

    摘要： The present invention relates to an in vitro system for physiological and metabolic evaluation of substances for use in living beings. The system includes one or more cell culture chambers, each containing cells in a culture medium and a gas-liquid exchange device for contacting the culture medium with oxygen-containing gas so that the culture medium absorbs that gas and desorbs carbon dioxide-containing gas. The conduit system conducts culture medium between the gas-liquid exchange device and the cell culture chambers. A circulation mechanism is used to circulate culture medium through the conduit system, the cell culture chambers, and the gas-liquid exchange device. In use, the substance to be evaluated is added to the culture medium of the system and circulated through the system. The cells in each of the cell culture chambers are then evaluated for effects resulting from the presence of the substance.

    摘要翻译： 本发明涉及用于生物的物质的生理和代谢评估的体外系统。 该系统包括一个或多个细胞培养室，每个细胞培养室均含有培养基中的细胞和用于使培养基与含氧气体接触的气液交换装置，使得培养基吸收该气体并解吸含二氧化碳的气体。 导管系统在气 - 液交换装置和细胞培养室之间传导培养基。 循环机构用于通过管道系统，细胞培养室和气液交换装置循环培养基。 在使用中，要评估的物质被添加到系统的培养基中并通过系统循环。 然后评估每个细胞培养室中的细胞的物质存在所产生的效果。